11:40 AM EST - ProMetic Life Sciences Inc. : announced today that it will be pursuing IPF as one of its PBI-4050 orphan indications. This decision follows the completion of a favorable external review of the extensive anti-fibrotic preclinical data generated to date by an independent panel of world experts on idiopathic pulmonary fibrosis and the analysis of the current market landscape. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.02 at $1.49.
